title: Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.
abstract: Fibroblast growth factor (FGF) signaling regulates cell proliferation, differentiation, survival, angiogenesis, and wound healing. Compelling evidence for deregulated FGF signaling in tumorigenesis continues to emerge, and a growing body of research suggests that FGF may also play an integral role in the resistance to anti-VEGF therapy. Although agents targeting FGF signaling are early in development, the potential to target both the VEGF and FGF pathways may translate into improvements in the clinical care of cancer patients.
authors.affiliation: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Lieu
authors.forename: John
authors.initials: J
authors.lastname: Heymach
authors.forename: Michael
authors.initials: M
authors.lastname: Overman
authors.forename: Hai
authors.initials: H
authors.lastname: Tran
authors.forename: Scott
authors.initials: S
authors.lastname: Kopetz
mesh_terms: D019008:Drug Resistance, Neoplasm; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic; D015398:Signal Transduction / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors